
Abbott Laboratories: shareholders and insiders
Price
$104.48
November 18, 2026Market cap $182B
What Ploutos Investor adds for Abbott Laboratories
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 6, 2026, from their own Form 4 filings.
Bought on the market
$4.4M
4 people
Sold on the market
$48M
7 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $4.4M by 4 people·sold $48M by 7 people
- 2025: no buys, sold $203.0K by 1 person
- 2026: bought $4.4M by 4 people, sold $48M by 7 people
- Nov 5, 2026Mary K MorelandEXECUTIVE VICE PRESIDENTKind
- Sep 23, 2026Kevin T ConroyDirectorKind
- Sep 2, 2026John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLERKind
- Sep 1, 2026John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLERKind
- Sep 1, 2026Philip P BoudreauEVP AND CFOKind
- Aug 25, 2026Robert B FordCHAIRMAN AND CEOKind
- Aug 25, 2026Robert B FordCHAIRMAN AND CEOKind
- Aug 25, 2026Robert B FordCHAIRMAN AND CEOKind
- Aug 25, 2026Robert B FordCHAIRMAN AND CEOKind
- Aug 12, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENTKind
- Aug 11, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENTKind
- Jun 30, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENTKind
- Jun 27, 2026Elizabeth C. CushmanEVP, GC AND SECRETARYKind
- May 7, 2026John G StrattonDirectorKind
- Apr 27, 2026Daniel J StarksKind
- Apr 23, 2026Philip P BoudreauEVP AND CFOKind
- Mar 2, 2026Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENTKind
- Mar 2, 2026John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLERKind
- Mar 2, 2026Mary K MorelandEXECUTIVE VICE PRESIDENTKind
- Mar 2, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENTKind
- Mar 2, 2026Eric ShroffSenior Vice PresidentKind
- Mar 2, 2026Elizabeth C. CushmanEVP, GC AND SECRETARYKind
- Feb 4, 2026Daniel J StarksKind
- Feb 4, 2026Daniel J StarksKind
- Jan 23, 2026Robert B FordCHAIRMAN AND CEOKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | Mary K MorelandEXECUTIVE VICE PRESIDENT | 3,500 | $116.00 | $406.0K | Form 4 | |
| Sep 23, 2026 | Kevin T ConroyDirector | 52.5K | $103.99 | $5.5M | Form 4 | |
| Sep 2, 2026 | John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER | 27 | $109.54 | $3.0K | Form 4 | |
| Sep 1, 2026 | John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER | 52 | $110.36 | $5.7K | Form 4 | |
| Sep 1, 2026 | Philip P BoudreauEVP AND CFO | 388 | $110.36 | $42.8K | Form 4 | |
| Aug 25, 2026 | Robert B FordCHAIRMAN AND CEO | 151.9K | $44.40 | $6.7M | Form 4 | |
| Aug 25, 2026 | Robert B FordCHAIRMAN AND CEO | 247.0K | $59.94 | $15M | Form 4 | |
| Aug 25, 2026 | Robert B FordCHAIRMAN AND CEO | 218.5K | $115.57 | $25M | Form 4 | |
| Aug 25, 2026 | Robert B FordCHAIRMAN AND CEO | 180.3K | $116.19 | $21M | Form 4 | |
| Aug 12, 2026 | Louis H. MorroneEXECUTIVE VICE PRESIDENT | 12 | $107.99 | $1.3K | Form 4 | |
| Aug 11, 2026 | Louis H. MorroneEXECUTIVE VICE PRESIDENT | 5,850 | $109.83 | $642.5K | Form 4 | |
| Jun 30, 2026 | Louis H. MorroneEXECUTIVE VICE PRESIDENT | 269 | $92.71 | $24.9K | Form 4 | |
| Jun 27, 2026 | Elizabeth C. CushmanEVP, GC AND SECRETARY | 560 | $94.12 | $52.7K | Form 4 | |
| May 7, 2026 | John G StrattonDirector | 2,000 | $86.82 | $173.6K | Form 4 | |
| Apr 27, 2026 | Daniel J Starks | 10.0K | $92.65 | $926.5K | Form 4 | |
| Apr 23, 2026 | Philip P BoudreauEVP AND CFO | 2,200 | $91.50 | $201.3K | Form 4 | |
| Mar 2, 2026 | Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENT | 885 | $115.58 | $102.3K | Form 4 | |
| Mar 2, 2026 | John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER | 585 | $115.58 | $67.6K | Form 4 | |
| Mar 2, 2026 | Mary K MorelandEXECUTIVE VICE PRESIDENT | 613 | $115.58 | $70.9K | Form 4 | |
| Mar 2, 2026 | Louis H. MorroneEXECUTIVE VICE PRESIDENT | 1,144 | $115.58 | $132.2K | Form 4 | |
| Mar 2, 2026 | Eric ShroffSenior Vice President | 709 | $115.58 | $81.9K | Form 4 | |
| Mar 2, 2026 | Elizabeth C. CushmanEVP, GC AND SECRETARY | 263 | $115.58 | $30.4K | Form 4 | |
| Feb 4, 2026 | Daniel J Starks | 4,967 | $109.14 | $542.1K | Form 4 | |
| Feb 4, 2026 | Daniel J Starks | 5,033 | $108.33 | $545.2K | Form 4 | |
| Jan 23, 2026 | Robert B FordCHAIRMAN AND CEO | 18.8K | $107.13 | $2.0M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 18, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ABT's officers and directors from 2006 up to November 18, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Vanguard Capital ManagementShare of class7.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Vanguard Capital Management | 7.50% | 131M | Apr 29, 2026 | 13G |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- The Vanguard Group0.00%Mar 26, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Southeastern Asset MgmtIn the quarter
- Citadel Advisors (Griffin)In the quarter+349%
- Point72 (Cohen)In the quarter
- Millennium Mgmt (Englander)In the quarter+172%
- AQR CapitalIn the quarter+167%
- D.E. ShawIn the quarter-72%
- Renaissance TechnologiesIn the quarter-33%
- Bridgewater (Dalio)In the quarter-49%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Southeastern Asset Mgmt | 840.7K | $76M | 3.98% | |
| Citadel Advisors (Griffin) | 8.60M | +349% | $780M | 0.45% |
| Point72 (Cohen) | 1.55M | $141M | 0.22% | |
| Millennium Mgmt (Englander) | 3.60M | +172% | $327M | 0.22% |
| AQR Capital | 4.19M | +167% | $381M | 0.13% |
| D.E. Shaw | 1.46M | -72% | $132M | 0.08% |
| Renaissance Technologies | 458.5K | -33% | $45M | 0.06% |
| Bridgewater (Dalio) | 59.8K | -49% | $5.4M | 0.02% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 1.00% of its shares outstanding were held short, +27.5% since the report before.
- Shares held short
- 17.39M
- 1.00%
- Since the report before13.63M on Sep 30, 2026
- +27.5%
- 1.8
- 9.77M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 22%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 9.88M
- Nov 15, 2023: Shares held short 12.08M
- Nov 30, 2023: Shares held short 11.75M
- Dec 15, 2023: Shares held short 12.31M
- Dec 29, 2023: Shares held short 11.88M
- Jan 12, 2024: Shares held short 10.55M
- Jan 31, 2024: Shares held short 12.70M
- Feb 15, 2024: Shares held short 14.29M
- Feb 29, 2024: Shares held short 14.92M
- Mar 15, 2024: Shares held short 15.72M
- Mar 28, 2024: Shares held short 14.48M
- Apr 15, 2024: Shares held short 12.94M
- Apr 30, 2024: Shares held short 14.48M
- May 15, 2024: Shares held short 14.77M
- May 31, 2024: Shares held short 14.50M
- Jun 14, 2024: Shares held short 11.62M
- Jun 28, 2024: Shares held short 13.00M
- Jul 15, 2024: Shares held short 10.75M
- Jul 31, 2024: Shares held short 13.63M
- Aug 15, 2024: Shares held short 12.68M
- Aug 30, 2024: Shares held short 12.75M
- Sep 13, 2024: Shares held short 13.36M
- Sep 30, 2024: Shares held short 11.83M
- Oct 15, 2024: Shares held short 13.98M
- Oct 31, 2024: Shares held short 14.07M
- Nov 15, 2024: Shares held short 12.05M
- Nov 29, 2024: Shares held short 13.57M
- Dec 13, 2024: Shares held short 12.10M
- Dec 31, 2024: Shares held short 14.32M
- Jan 15, 2025: Shares held short 14.97M
- Jan 31, 2025: Shares held short 18.24M
- Feb 14, 2025: Shares held short 22.31M
- Feb 28, 2025: Shares held short 22.93M
- Mar 14, 2025: Shares held short 21.88M
- Mar 31, 2025: Shares held short 21.79M
- Apr 15, 2025: Shares held short 21.69M
- Apr 30, 2025: Shares held short 21.12M
- May 15, 2025: Shares held short 22.26M
- May 30, 2025: Shares held short 20.09M
- Jun 13, 2025: Shares held short 20.80M
- Jun 30, 2025: Shares held short 19.43M
- Jul 15, 2025: Shares held short 19.06M
- Jul 31, 2025: Shares held short 18.33M
- Aug 15, 2025: Shares held short 17.11M
- Aug 29, 2025: Shares held short 17.75M
- Sep 15, 2025: Shares held short 18.07M
- Sep 30, 2025: Shares held short 18.17M
- Oct 15, 2025: Shares held short 19.36M
- Oct 31, 2025: Shares held short 20.17M
- Nov 14, 2025: Shares held short 19.14M
- Nov 28, 2025: Shares held short 18.49M
- Dec 15, 2025: Shares held short 15.88M
- Dec 31, 2025: Shares held short 17.40M
- Jan 15, 2026: Shares held short 19.91M
- Jan 30, 2026: Shares held short 18.73M
- Feb 13, 2026: Shares held short 17.20M
- Feb 27, 2026: Shares held short 18.23M
- Mar 13, 2026: Shares held short 19.95M
- Mar 31, 2026: Shares held short 23.83M
- Apr 15, 2026: Shares held short 21.75M
- Apr 30, 2026: Shares held short 22.54M
- May 15, 2026: Shares held short 23.22M
- May 29, 2026: Shares held short 22.04M
- Jun 15, 2026: Shares held short 21.97M
- Jun 30, 2026: Shares held short 23.39M
- Jul 15, 2026: Shares held short 24.85M
- Jul 31, 2026: Shares held short 22.62M
- Aug 14, 2026: Shares held short 20.38M
- Aug 31, 2026: Shares held short 22.13M
- Sep 15, 2026: Shares held short 19.91M
- Sep 30, 2026: Shares held short 13.63M
- Oct 15, 2026: Shares held short 17.39M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading36.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 36.1% of the shares in the reported trades were short sales, against 43.0% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 36.1%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 43.0%
- Change
- -6.9 pts
- Short sales a dayon average, of 3.01M shares
- 1.08M
- More than atof 3,656 US-listed companies, same days
- 12%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 43%
- Oct 13, 2026: Short sales 34.7%
- Oct 14, 2026: Short sales 40.1%
- Oct 15, 2026: Short sales 40.3%
- Oct 16, 2026: Short sales 34.8%
- Oct 19, 2026: Short sales 27.9%
- Oct 20, 2026: Short sales 54%
- Oct 21, 2026: Short sales 50.3%
- Oct 22, 2026: Short sales 48.4%
- Oct 23, 2026: Short sales 36.5%
- Oct 26, 2026: Short sales 51%
- Oct 27, 2026: Short sales 52.6%
- Oct 28, 2026: Short sales 43%
- Oct 29, 2026: Short sales 31.5%
- Oct 30, 2026: Short sales 59.7%
- Nov 2, 2026: Short sales 56.8%
- Nov 3, 2026: Short sales 34.6%
- Nov 4, 2026: Short sales 37.8%
- Nov 5, 2026: Short sales 38.2%
- Nov 6, 2026: Short sales 33.8%
- Nov 9, 2026: Short sales 34.8%
- Nov 10, 2026: Short sales 31.5%
- Nov 11, 2026: Short sales 38.1%
- Nov 12, 2026: Short sales 17.9%
- Nov 13, 2026: Short sales 25.9%
- Nov 16, 2026: Short sales 24.1%
- Nov 17, 2026: Short sales 26.2%
- Nov 18, 2026: Short sales 32.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Daniel J StarksDirectorDirectly6.75M
- Robert B FordCHAIRMAN AND CEODirectly306.5K
- Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENTDirectly211.3K
- Hubert L AllenEXECUTIVE VICE PRESIDENTDirectly184.8K
- Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENTDirectly146.4K
- Mary K MorelandEXECUTIVE VICE PRESIDENTDirectly118.1K
- Philip P BoudreauEVP AND CFODirectly80.1K
- Kevin T ConroyDirectorDirectly81.2K
- Andrea F WainerRETIRED EVPDirectly74.4K
- Lisa D EarnhardtEVP AND GROUP PRESIDENTDirectly71.9K
- Louis H. MorroneEXECUTIVE VICE PRESIDENTDirectly70.7K
- Eric ShroffSenior Vice PresidentDirectly39.2K
- Elizabeth C. CushmanEVP, GC AND SECRETARYDirectly38.0K
- Sally E. BlountDirectorDirectly34.1K
- John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLERDirectly24.5K
- John G StrattonDirectorDirectly23.3K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Daniel J StarksDirector | 6.75M | – | Apr 27, 2026 | Form 4 |
| Robert B FordCHAIRMAN AND CEO | 306.5K | 216.2K | Aug 25, 2026 | Form 4 |
| Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT | 211.3K | – | May 10, 2024 | Form 4 |
| Hubert L AllenEXECUTIVE VICE PRESIDENT | 184.8K | – | Jan 30, 2025 | Form 4 |
| Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENT | 146.4K | – | Mar 2, 2026 | Form 4 |
| Mary K MorelandEXECUTIVE VICE PRESIDENT | 118.1K | – | Nov 5, 2026 | Form 4 |
| Philip P BoudreauEVP AND CFO | 80.1K | 2,200 | Sep 1, 2026 | Form 4 |
| Kevin T ConroyDirector | 81.2K | – | Sep 23, 2026 | Form 4 |
| Andrea F WainerRETIRED EVP | 74.4K | – | Mar 3, 2025 | Form 4 |
| Lisa D EarnhardtEVP AND GROUP PRESIDENT | 71.9K | – | Mar 7, 2025 | Form 4 |
| Louis H. MorroneEXECUTIVE VICE PRESIDENT | 70.7K | – | Aug 12, 2026 | Form 4 |
| Eric ShroffSenior Vice President | 39.2K | – | Mar 2, 2026 | Form 4 |
| Elizabeth C. CushmanEVP, GC AND SECRETARY | 38.0K | – | Jun 27, 2026 | Form 4 |
| Sally E. BlountDirector | 34.1K | – | Apr 30, 2025 | Form 4 |
| John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER | 24.5K | – | Sep 2, 2026 | Form 4 |
| John G StrattonDirector | 23.3K | – | May 7, 2026 | Form 4 |
A lower bound: it counts only the 16 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Hubert L. AllenExecutive Vice President, General Counsel and SecretaryWhat happenedAdoptedMay 10, 2024Shares157.4K
- Robert E. Funck, Jr.Executive Vice President, FinanceWhat happenedAdoptedMay 10, 2024Shares45.0K
- Andrea F. WainerExecutive Vice President, Rapid and Molecular DiagnosticsWhat happenedAdoptedMay 1, 2023Shares–
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Hubert L. AllenExecutive Vice President, General Counsel and Secretary | AdoptedMay 10, 2024 | Feb 19, 2025 | 157.4K | 10-Q |
| Robert E. Funck, Jr.Executive Vice President, Finance | AdoptedMay 10, 2024 | Feb 19, 2025 | 45.0K | 10-Q |
| Andrea F. WainerExecutive Vice President, Rapid and Molecular Diagnostics | AdoptedMay 1, 2023 | 426 days | – | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$24M
Actually paid: $27M
$7.5M
Actually paid: $7.6M
–
Adjusted Diluted EPS
From the proxy statement (DEF 14A) of Mar 13, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-QAmount$1.0B
- Dec 31, 202510-KAmount$301M
- Sep 30, 202510-QAmount$303M
- Dec 31, 202410-KAmount$366M
- Sep 30, 202410-QAmount$750M
- Dec 31, 202310-KAmount$300M
- Jun 30, 202310-QAmount$425M
- Dec 31, 202210-KAmount$682M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-Q | 11.60M | $89.70 | $1.0B | $5.6B | 10-Q |
| Dec 31, 202510-K | 2.34M | $128.68 | $301M | $6.7B | 10-K |
| Sep 30, 202510-Q | 2.43M | $124.76 | $303M | $7.0B | 10-Q |
| Dec 31, 202410-K | 3.19M | $114.69 | $366M | $7.3B | 10-K |
| Sep 30, 202410-Q | 7.01M | $107.05 | $750M | $659M | 10-Q |
| Dec 31, 202310-K | 2.77M | $108.22 | $300M | $1.4B | 10-K |
| Jun 30, 202310-Q | 4.02M | $105.63 | $425M | $1.7B | 10-Q |
| Dec 31, 202210-K | 6.55M | $104.08 | $682M | $2.4B | 10-K |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 8 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026Apr 27, 2026For90.7%
- 2025Apr 28, 2025For90.4%
- 2024Apr 29, 2024For89.4%
- 2023May 2, 2023For90.5%
- 2022May 2, 2022For91.8%
- 2021Apr 26, 2021For92.4%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026Apr 27, 2026 | 90.7% | 1.23B | 126M | 4.88M | 178M | 8-K |
| 2025Apr 28, 2025 | 90.4% | 1.22B | 131M | 6.99M | 173M | 8-K |
| 2024Apr 29, 2024 | 89.4% | 1.21B | 144M | 4.08M | 178M | 8-K |
| 2023May 2, 2023 | 90.5% | 1.21B | 127M | 7.32M | 180M | 8-K |
| 2022May 2, 2022 | 91.8% | 1.23B | 110M | 7.40M | 186M | 8-K |
| 2021Apr 26, 2021 | 92.4% | 1.25B | 103M | 7.19M | 196M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it. 1 filing(s) not read, as the table is not in the usual shape.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHIiShares U.S. Medical Devices ETFWeight in the fund16.93%
- SCHDSchwab U.S. Dividend Equity ETFWeight in the fund4.68%
- IYHiShares U.S. Healthcare ETFWeight in the fund3.02%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund2.75%
- VHTVanguard Health Care Index FundWeight in the fund2.66%
- QLTYGMO U.S. Quality ETFWeight in the fund2.57%
- HDViShares Core High Dividend ETFWeight in the fund2.29%
- IXJiShares Global Healthcare ETFWeight in the fund2.05%
- NOBLProShares S&P 500 Dividend Aristocrats ETFWeight in the fund1.55%
- DGROiShares Core Dividend Growth ETFWeight in the fund1.10%
62 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 3,183
- Q4 2025: Managers 3,295
- Q1 2026: Managers 3,121
- Q2 2026: Managers 2,970
Institutional investors by quarter
The fund managers holding ABT, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 2,970 managers held 1.38B shares, worth $125B. During the quarter 190 opened a position, 341 closed one, 1,027 added and 1,364 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+4.7%
- Vanguard Capital ManagementIn the quarter+0.7%
- State StreetIn the quarter+1.7%
- Charles Schwab Investment ManagementIn the quarter+31%
- Vanguard Portfolio ManagementIn the quarter+2.2%
- Geode Capital ManagementIn the quarter+0.2%
- Capital Research Global InvestorsIn the quarter-26%
- Capital International InvestorsIn the quarter-7.6%
- Morgan StanleyIn the quarter-12%
- Norges BankIn the quarter-0.4%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 153M | +4.7% | $13.8B |
| Vanguard Capital Management | 114M | +0.7% | $10.3B |
| State Street | 80.93M | +1.7% | $7.3B |
| Charles Schwab Investment Management | 59.67M | +31% | $5.4B |
| Vanguard Portfolio Management | 49.02M | +2.2% | $4.4B |
| Geode Capital Management | 39.22M | +0.2% | $3.5B |
| Capital Research Global Investors | 36.91M | -26% | $3.3B |
| Capital International Investors | 34.65M | -7.6% | $3.1B |
| Morgan Stanley | 26.61M | -12% | $2.4B |
| Norges Bank | 23.35M | -0.4% | $2.1B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Abbott Laboratories's filings show?
Who buys and sells is one part of Abbott Laboratories's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ABT's insiders bought or sold?
From Jun 18, 2026 to Nov 6, 2026 Abbott Laboratories's insiders bought $173.6K and sold $47M of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold ABT?
8 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $780M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.